PharmaCyte Biotech
PMCB
31 hedge funds and large institutions have $2.4M invested in PharmaCyte Biotech in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 2 closing their positions.
350% more call options, than puts
Call options by funds: $18K | Put options by funds: $4K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
7% more funds holding
Funds holding: 29 → 31 (+2)
5.79% more ownership
Funds ownership: 7.23% → 13.02% (+5.8%)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
31% less capital invested
Capital invested by funds: $3.47M → $2.4M (-$1.07M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$266K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$248K |
| 3 |
EPM
Equitec Proprietary Markets
Chicago,
Illinois
|
+$54.3K |
| 4 |
Renaissance Technologies
New York
|
+$17.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ayrton Capital
Westport,
Connecticut
|
-$471K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$120K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$75.3K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$37.4K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$36.4K |
PMCB Hedge Fund Activity: Q3 2023 in Review
31 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q3 2023, worth a combined $2.4M — down 31% from $3.47M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PMCB positions and 2 closed out — a net gain of 2 holders — while 8 added to existing stakes and 9 trimmed.
The largest buyer was K2 Principal Fund, adding an estimated $266K. The largest seller was Ayrton Capital, cutting an estimated $471K.
- 31 institutional investors held PharmaCyte Biotech (PMCB) as of Q3 2023, up from 29 in Q2 2023.
- Funds reported $2.4M of PharmaCyte Biotech stock for Q3 2023, down 31% quarter-over-quarter.
- 4 funds opened new PharmaCyte Biotech positions in Q3 2023 and 2 closed out, a net change of +2 holders.
- The largest PharmaCyte Biotech buyer in Q3 2023 was K2 Principal Fund, an estimated $266K added.
- The largest PharmaCyte Biotech seller in Q3 2023 was Ayrton Capital, an estimated $471K sold.
Based on aggregated 13F filings for Q3 2023.